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ABSTRACT
FXII is considered a potential prothrombotic, proinflammatory and profibrinolytic protease. Evidence supports
the concept that women with reduced plasma FXII level may be at high risk of developing premature delivery.
FXII C46T polymorphism influences venous thrombosis and puerperium in asymptomatic women with no
history of miscarriages. The prevalence of preeclampsia in obese women is high. The aim of this study was to
examine whether there would be a correlation between the factor XII and dietary fatty acid. Immunochemical
methods and functional techniques using a chromogenic peptide substrate assay were used. Although our
findings were inconclusive, further research is needed.

INTRODUCTION & BACKGROUND
FXII (Hageman Factor) activates the
plasma Kallikrein-Kinin System (KKS). This
plasma protein is involved in the contact
activation (intrinsic) pathway of blood
coagulation. Activation of FXII to FXIIa
begins the coagulation cascade, with the
eventual formation of a fibrin clot.
Circulating fatty acids have been proposed
to provide a substrate for FXII activation1.
Once activated, FXIIa, can catalyze
Prekallikrein (PK) to kallikrein. Kallikrein then
acts on High molecular weight Kininogen
(HK) to generate Bradykinin (BK). Elevated
BK has been shown to play a significant role
in the pathogenesis of Hereditary
Angioedema (HAE), and may be implicated
in preeclamptic swelling. In the absence of
the C1-inhibitor protein, there is
uncontrolled generation of kallikrein and

BK, which leads to severe edema in HAE
patients.
FXII is converted to FXIIa in an excess
manner under pathophysiological
conditions. FXIIa is significantly elevated in
diseases such as non-alcoholic fatty liver
disease2, diabetes mellitus, and diabetic
retinopathy3. As these are diseases where
fatty acids have been shown to be
elevated4,5, our lab investigated the
relationship between saturated,
monounsaturated, and polyunsaturated fatty
acids and FXII activation. Following
experiments on fatty acids, we begun
characterizing a new FXIIa inhibitor. Several
hundred compounds from the National
Center for Natural Products Research were
screened in a double blind manner. Five
compounds were found to inhibit FXIIa to
various extents. Among these lead
compounds, G1 avidly inhibited FXIIa.

FIGURE 1. The Kallikrein-Kinin system can be activated
locally and systemically by FXII. Feener, E. P., et. Al (2013).
Thrombosis and Haemostasis, 110(3), 434-441.

PURPOSE
The goal of the current study is to
determine the effects of fatty acids on
plasma proteins, specifically FXII.
Subsequently, the inhibitory characteristics
of G1 were determined in order to
understand how this compound interacts
with different proteins. It is our hope that
G1 will prove to be a selective inhibitor of
FXIIa, and thus be a novel therapeutic for
treating diseases such as Hereditary
Angioedema.
MATERIAL & METHODS
Chromegenic FXIIa Activity Assay: The effect
of fatty acids on the activity of FXIIa was
quantified using a chromogenic assay. Effect
of G1, a new inhibitor of plasma enzymes, was
also characterized with the use of a
chromogenic assay in the presence of
kallikrein, FXIa, and FXIIa FXIIa (Enzyme
Research Laboratories, South Bend, IN, USA)
in fluid phase. The effect of fatty acids on
FXIIa activity was determined using the
chromogenic substrate CS-31(02) (Aniara

Diagnostica, West Chester, OH, USA). In this
experiment, 9 nM FXIIa was incubated with
the chromogenic substrate CS-31(02).
Subsequently, free para-nitroaniline was
measured. Kallikrein (1 nM) and FXIa (18 nM)
were measured in a similar manner, utilizing
0.23 mM CS-31(02) and 0.43 mM S2366
respectively. Plasma proteins were incubated
with their respective enzyme in the absence or
presence of increasing concentrations of fatty
acids or potential inhibitory compound G1
with a final volume of 100 µL HEPES-NaHCO3
buffer (137 mM NaCl; 3 mM KCl; 14.7 mM
HEPES; 1 mM MgCl2; 2 mM CaCl2; 5.5 mM
glucose; and 0.1% gelatin, pH 7.1). For FXIa
activity, (18 nM) FXIa (Enzyme Research
Laboratories) was incubated with 0.43 mM
S2366 (Glu-Pro-Arg-p-nitroanalide) in the
absence or presence of the inhibitor. After 1 h
of incubation at 37°C, the activity of kallikrein,
FXIIa or FXIa was measured as a change in
absorbance at OD 405 nm using BioTek
ELx800 Absorbance Microplate Reader
(Winooski, VT, USA). Data were analyzed
using GraphPad Prism software (GraphPad
Software, Inc., La Jolla, CA, USA).

RESULTS
Enzyme Kinetic Determination: Optimum concentrations of enzymes and substrates were
determined. Once proper concentrations were specified, experimental time length was
established through a time course.

FIGURE 2. A) FXIIa activity was assayed to determine the optimal concentration of FXIIa in
the presence of CS-31(02). Due to this experiment, 9 nM FXIIa was used in subsequent
experiments to measure changes in FXIIa activity. B) The Km range obtained for CS-31(02)
in the presence of FXIIa was 0.4375 to 0.5899 mM. For subsequent measurements of FXIIa
activity, the final concentration of CS-31(02) equaled 0.43 mM. C) A time course using 9 nM
FXIIa and 0.43 mM CS-31(02) was used to determine the ideal incubation time for the
following experiments. Following this result, an incubation time of 1 hour was used for all
experiments utilizing FXIIa, FXIa, and Kallikrein.

FIGURE 3. Effect of fatty acid on FXIIa activity. Fatty acids were tested (replicates=3) to
determine their effects on the catalytic activity of FXIIa. No fatty acids were found to show
inhibition or stimulation of FXIIa. Data are presented as Mean ± SEM.

FIGURE 4. A) Determination of enzyme inhibition by compound G1. FXIIa and FXIa activity
were reduced significantly by compound G1. However, G1 did not inhibit Kallikrein, which
indicates its specificity for FXIIa and FXIa. B) G1 does not inhibit Kallikrein activity. Kallistop,
a synthetic Kallikrein inhibitor was used to show that Kallikrein was not inhibited by G1.
Data are presented as Mean ± SEM.

DISCUSSION
Substrate hydrolysis occurred in a time and
concentration dependent manner. Fatty
acids were not found to modulate the
activity of FXIIa. G1 was found to inhibit
coagulation factors XIIa and XIa, but not

kallikrein. Further experiments are needed
to determine fatty acid modulation of FXIIa,
along with the effects of G1 on downstream
components of the blood coagulation
pathway and the Kallikrein-Kinin System.
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